Helping Patients Achieve Their Vision Goals
We support patients throughout every step of the SING IMT patient journey, including diagnosis, evaluation, implantation, and rehabilitation.
The SING IMT is approved for late-stage AMD patients who are 55 years of age or older CE Referenced Countries and is not currently FDA Approved in the United States. Because AMD is a progressive disease, over time, patients have adapted with the loss of vision in the central field of vision. Before receiving the SING IMT, patients must understand the possible and realistic outcomes post-op and commit to working with their ophthalmological team to use visual techniques and exercises to maximize the effectiveness of SING IMT.